Ubs Group Ag Galectin Therapeutics Inc Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Ubs Group Ag holds 14,332 shares of GALT stock, worth $16,195. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,332

Previous 13,207 8.52%

Holding current value

$16,195

Previous $29,000 34.48%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.04 - $2.86 $2,295 - $3,217	1,125 Added 8.52%	14,332 $39,000
Q2 2024 Aug 13, 2024	BUY	$2.13 - $4.2 $28,130 - $55,469	13,207 New	13,207 $29,000
Q4 2023 Feb 09, 2024	BUY	$1.6 - $2.18 $995 - $1,355	622 New	622 $1,000
Q4 2022 Feb 08, 2023	BUY	$1.03 - $1.66 $5,727 - $9,231	5,561 New	5,561 $6,000
Q2 2022 Aug 10, 2022	BUY	$1.19 - $1.74 $2,113 - $3,090	1,776 New	1,776 $2,000
Q4 2021 Feb 14, 2022	SELL	$2.07 - $3.8 $4,115 - $7,554	-1,988 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$2.59 - $4.15 $2,558 - $4,100	988 Added 98.8%	1,988 $8,000
Q2 2021 Aug 13, 2021	SELL	$2.07 - $5.1 $11,289 - $27,815	-5,454 Reduced 84.51%	1,000 $3,000
Q1 2021 May 12, 2021	SELL	$1.96 - $2.57 $33,543 - $43,982	-17,114 Reduced 72.62%	6,454 $14,000
Q4 2020 Feb 11, 2021	BUY	$2.24 - $2.87 $46,081 - $59,041	20,572 Added 686.65%	23,568 $53,000
Q3 2020 Nov 12, 2020	SELL	$2.53 - $3.64 $23,794 - $34,234	-9,405 Reduced 75.84%	2,996 $8,000
Q2 2020 Jul 31, 2020	SELL	$1.66 - $3.15 $20,929 - $39,715	-12,608 Reduced 50.41%	12,401 $38,000
Q1 2020 May 01, 2020	SELL	$1.51 - $3.0 $39,728 - $78,930	-26,310 Reduced 51.27%	25,009 $49,000
Q4 2019 Feb 14, 2020	BUY	$2.79 - $4.32 $49,915 - $77,289	17,891 Added 53.52%	51,319 $147,000
Q3 2019 Nov 14, 2019	BUY	$3.0 - $4.05 $46,044 - $62,159	15,348 Added 84.89%	33,428 $123,000
Q2 2019 Aug 14, 2019	BUY	$3.61 - $5.0 $40,995 - $56,780	11,356 Added 168.89%	18,080 $75,000
Q1 2019 May 14, 2019	SELL	$3.86 - $6.02 $9,194 - $14,339	-2,382 Reduced 26.16%	6,724 $34,000
Q4 2018 Feb 14, 2019	BUY	$3.43 - $5.74 $24,527 - $41,046	7,151 Added 365.78%	9,106 $31,000
Q3 2018 Nov 14, 2018	SELL	$3.68 - $6.93 $19,305 - $36,354	-5,246 Reduced 72.85%	1,955 $12,000
Q2 2018 Aug 14, 2018	BUY	$3.16 - $9.16 $3,409 - $9,883	1,079 Added 17.62%	7,201 $46,000
Q1 2018 May 15, 2018	BUY	$3.78 - $5.97 $23,141 - $36,548	6,122 New	6,122 $29,000
Q4 2017 Feb 14, 2018	SELL	$1.54 - $3.34 $10,230 - $22,187	-6,643 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$1.67 - $2.3 $7,064 - $9,729	4,230 Added 175.3%	6,643 $14,000
Q2 2017 Aug 14, 2017	SELL	N/A	-1,292 Reduced 34.87%	2,413 $6,000
Q1 2017 Nov 14, 2017	BUY	N/A	3,705	3,705 $9,000

Others Institutions Holding GALT

# of Institutions

Shares Held

9.65M

Call Options Held

1.16M

Put Options Held

1.98M

View Full List

About GALECTIN THERAPEUTICS INC

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $67.2M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

More about GALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account